GLP-1-based medications have changed what is possible in the medical management of obesity and type 2 diabetes. Medications such as semaglutide and liraglutide, and dual GIP/GLP-1 receptor agonists like tirzepatide can reduce appetite, improve glycemic control, and result in substantial weight loss. But the number on the scale tells only part of the story.
When body weight decreases, the body does not lose fat exclusively. Some lean tissue may also be lost, and substantial weight reduction can influence bone metabolism. This means that the quality of weight loss matters alongside its magnitude. The goal of GLP-1 therapy should not simply be to reach the lowest possible weight. It should be to reduce excess body fat while protecting muscle strength, physical function, bone health, nutritional status, and the ability to maintain a healthy weight over time.
Lean Mass Is Not the Same as Muscle
The terms lean mass and muscle mass are often used interchangeably, but they are not identical. Lean mass measured by dual-energy X-ray absorptiometry, or DXA, includes:
- Skeletal muscle
- Organs
- Connective tissue
- Body water
- Other nonfat tissues
A reduction in measured lean mass therefore does not necessarily mean that an equivalent amount of skeletal muscle has been lost. Changes in hydration, glycogen storage, liver size, and organ fat can influence lean-mass measurements. This distinction is important because reports that a certain percentage of GLP-1-related weight loss comes from “lean mass” are sometimes interpreted as evidence that all of that loss is muscle. Current evidence does not support that conclusion. At the same time, lean-tissue loss should not be dismissed. Skeletal muscle is essential for strength, mobility, glucose regulation, metabolic health, injury prevention, and independence with aging. The clinical goal is therefore to monitor not only body composition but also whether a person is maintaining strength and physical function.
What Does Current Research Show?
In an exploratory DXA substudy of the STEP 1 trial, adults receiving semaglutide 2.4 mg experienced a 15% reduction in body weight over 68 weeks. Total fat mass declined by 19.3%, visceral fat mass declined by 27.4%, and total lean body mass declined by 9.7%. Although absolute lean mass decreased, lean tissue represented a greater proportion of total body weight after treatment. A more recent DXA substudy of the SURMOUNT-1 trial evaluated body-composition changes in participants receiving tirzepatide. At 72 weeks, body weight decreased by 21.3%, fat mass by 33.9%, and lean mass by 10.9%. Approximately 75% of the weight lost was fat mass and 25% was lean mass a proportion similar to that observed in the placebo group.
These studies suggest several important points:
- GLP-1-based therapy generally produces a much greater reduction in fat mass than lean mass.
- Some loss of lean tissue occurs during substantial weight loss.
- Lean-mass loss is not unique to GLP-1 therapy; it also occurs with calorie restriction, bariatric surgery, and other forms of weight reduction.
- The speed and magnitude of GLP-1-related weight loss make muscle-preservation strategies especially important.
- Body-composition measurements should ideally be interpreted alongside strength, mobility, and physical-performance assessments.
The people likely to require the closest monitoring include older adults, postmenopausal women, individuals with sarcopenia or osteoporosis, people following highly restrictive diets, and anyone experiencing rapid weight loss, prolonged nausea, or inadequate food intake.
Resistance Exercise Is a Biological Signal to Preserve Muscle
Adequate protein provides the building blocks needed for muscle tissue, but resistance exercise provides the signal that encourages the body to retain and strengthen that tissue. Without regular muscular loading, the body has less reason to preserve metabolically expensive muscle during an energy deficit. Resistance training stimulates muscle-protein synthesis, supports strength, improves insulin sensitivity, and helps maintain physical function.
Effective resistance exercise does not necessarily require heavy bodybuilding-style workouts. Depending on health status and experience, it may include:
- Squats or sit-to-stand movements
- Rows
- Chest presses or modified push-ups
- Hip hinges or deadlift variations
- Step-ups
- Overhead presses
- Resistance-band exercises
- Weight machines
- Free weights
- Supervised body-weight training
A reasonable general goal for many adults is resistance training at least two days per week, targeting the major muscle groups. The appropriate intensity, volume, and exercise selection should be adjusted for age, mobility, cardiovascular health, orthopedic limitations, and previous training experience. Progression matters. Muscles and bones adapt when they are challenged beyond their usual workload. As a movement becomes easier, resistance, repetitions, sets, or exercise complexity may need to increase gradually. For older adults or individuals at elevated fracture risk, an exercise physiologist or physical therapist can help develop a safer program that also includes balance and fall-prevention training.
Exercise May Protect Bone as Well as Muscle
Weight-bearing tissues respond to mechanical loading. When body weight decreases, the skeleton experiences less mechanical load. Calorie restriction and weight loss can also alter hormones and increase bone turnover, potentially contributing to reductions in bone mineral density. A 2024 randomized clinical trial provides particularly relevant evidence. Adults with obesity first completed an eight-week low-calorie diet and were then assigned to exercise, liraglutide, exercise plus liraglutide, or placebo for one year. The combination of exercise and liraglutide produced the greatest weight and fat loss while preserving bone mineral density at the hip, spine, and forearm. Liraglutide without exercise reduced hip and spine bone mineral density compared with exercise alone, despite similar weight loss. Exercise alone also increased lean mass while preserving bone density.
This study should not be generalized to every GLP-1 medication or every patient. It involved liraglutide, and bone outcomes were part of a secondary analysis. Nevertheless, it provides strong support for including structured exercise alongside GLP-1 therapy rather than relying on medication alone.
Exercises that may benefit bone include:
- Progressive resistance training
- Brisk walking
- Stair climbing
- Hiking
- Dancing
- Jogging, when appropriate
- Jumping or other impact activities for suitable individuals
Walking is valuable for cardiovascular health, energy expenditure, mood, and mobility, but walking alone may not provide enough resistance to optimize muscle preservation. A complete program should ideally include both aerobic activity and progressive resistance exercise.
Protein: Prioritizing Quality and Distribution
Because GLP-1 medications reduce appetite and food intake, some individuals may find it difficult to consume enough protein. Early fullness can make a large serving of meat, fish, or other dense protein foods difficult to tolerate. A 2025 joint clinical advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society proposed an absolute protein target of approximately 80–120 grams per day as one practical approach for many adults using GLP-1 medications.
This range is not appropriate for everyone. Protein requirements should be individualized according to:
- Body size and body composition
- Age
- Physical activity
- Kidney and liver function
- Total energy intake
- Weight-loss rate
- Medical conditions
- Overall nutritional status
People with kidney disease or certain other medical conditions should receive individualized guidance before substantially increasing protein intake.
Practical protein sources include the following:
- Eggs
- Fish and seafood
- Poultry
- Lean meat
- Greek yogurt and cottage cheese
- Milk or fortified soy milk
- Tofu and tempeh
- Beans, peas, and lentils
- Edamame
- Nuts and seeds
- Nutritionally appropriate protein powders or shakes
Protein may be better tolerated when spread across several smaller meals. Eating the protein-containing portion first can also help when early fullness prevents completion of the meal. However, “protein first” should not become “protein only.” A diet dominated by protein shakes, bars, or meat may provide inadequate fiber, calcium, potassium, magnesium, vitamin C, and phytonutrients. Protein should be part of a varied, nutrient-dense dietary pattern.
Calcium: The Structural Mineral
Calcium is a major structural component of bone, but it is also required for muscle contraction, nerve signaling, and vascular function. When food intake decreases substantially, calcium intake may fall, particularly if dairy products, fortified alternatives, leafy vegetables, tofu, or fish with edible bones are rarely consumed. According to the National Institutes of Health, recommended calcium intake for most adults ranges from 1,000–1,200 milligrams per day, depending on age and sex. Adult women aged 51–70 and all adults aged 71 and older generally require 1,200 milligrams per day.
Food sources include:
- Milk
- Yogurt
- Cheese
- Calcium-fortified plant-based milk
- Calcium-set tofu
- Sardines or canned salmon with bones
- Kale, bok choy, and certain other greens
- Beans and almonds
- Calcium-fortified foods
Calcium from food is generally preferred because calcium-rich foods often provide protein and other nutrients simultaneously. Supplementation may be appropriate when dietary intake is inadequate, but more is not necessarily better. Excessive supplemental calcium may increase the risk of kidney stones and could create other health concerns in susceptible individuals. Calcium supplementation should be based on the gap between dietary intake and individual requirements, not automatically added at a high dose.
Vitamin D: Supporting Calcium Absorption and Muscle Function
Vitamin D helps the intestine absorb calcium and supports normal bone mineralization. It also contributes to normal muscle and immune function. The recommended dietary allowance for adults generally ranges from 600–800 IU, or 15–20 micrograms, per day depending on age. However, individual requirements may differ based on:
- Baseline vitamin D status
- Sun exposure
- Skin pigmentation
- Age
- Body size
- Geographic location
- Malabsorption conditions
- Liver or kidney disease
- Medication use
Vitamin D is naturally present in relatively few foods. Sources include fatty fish, egg yolks, fortified milk, fortified plant-based beverages, and certain fortified cereals. Obesity is itself associated with a higher prevalence of low vitamin D status. In addition, reduced food intake during GLP-1 therapy may make it more difficult to obtain sufficient vitamin D. A 2025 observational study of adults using GLP-1 receptor agonists found that vitamin D deficiency was the most frequently documented nutritional deficiency during the first year of therapy.
That finding does not establish that the medication directly caused the deficiency. It does support consideration of baseline assessment and follow-up testing in individuals at elevated risk. High-dose vitamin D should not be used without medical oversight. Excessive intake can cause hypercalcemia and damage the kidneys and other tissues.
What Do We Know About GLP-1 Medications and Fracture Risk?
The direct relationship between GLP-1 receptor agonists and bone health remains uncertain. Some laboratory and animal studies suggest that GLP-1 signaling could have favorable effects on bone metabolism. Human studies, however, have produced mixed findings. A 2025 systematic review and meta-analysis found that GLP-1 receptor agonist use was not significantly associated with increased fracture risk overall. Other analyses have reported neutral or possibly reduced fracture risk.
These results are somewhat reassuring, but they do not eliminate concern about bone loss associated with substantial or rapid weight reduction. Many studies were conducted in people with diabetes, used different GLP-1 medications and doses, followed participants for limited periods, or recorded too few fractures to draw definitive conclusions. Bone health should therefore be evaluated according to the person’s complete risk profile rather than assuming the medication is either protective or harmful.
Factors warranting closer attention include:
- Previous fragility fracture
- Osteopenia or osteoporosis
- Postmenopausal status
- Older age
- Low body weight after treatment
- Rapid or excessive weight loss
- Smoking
- Heavy alcohol use
- Long-term corticosteroid therapy
- Low calcium or vitamin D intake
- Family history of osteoporosis
- Limited physical activity
- Recurrent falls
- Conditions affecting nutrient absorption
For individuals at increased risk, clinicians may consider vitamin D testing, dietary assessment, DXA scanning, fall-risk evaluation, or other monitoring based on established osteoporosis guidelines.
Maintaining a Healthy Weight Without Repeated Loss and Regain
Healthy weight maintenance is part of protecting muscle and bone. Repeated cycles of rapid weight loss and regain may make it more difficult to preserve lean tissue, particularly if weight is lost without resistance training and later regained primarily as fat. The objective should not be to remain in a constant state of aggressive calorie restriction.
After active weight loss, nutritional priorities should gradually shift toward:
- Stabilizing energy intake
- Maintaining consistent protein consumption
- Continuing resistance training
- Preserving dietary variety
- Supporting bone-building nutrients
- Monitoring strength and physical function
- Avoiding unnecessarily rapid further weight loss
- Establishing a realistic long-term weight range
The STEP 1 extension found that participants regained an average of approximately two-thirds of their previous weight loss within one year after semaglutide and structured lifestyle support were withdrawn. More recent evidence continues to show that weight regain is common after obesity medications are discontinued.
This is not a personal failure. Obesity is a chronic disease influenced by biological, environmental, behavioral, and social factors. Some individuals may require long-term medication, while others may discontinue or change treatment because of side effects, pregnancy planning, cost, access, medical considerations, or personal preference. In every situation, the habits developed during treatment especially resistance exercise, protein adequacy, dietary quality, and regular monitoring, remain important.
Measuring Success Beyond the Scale
Body weight is useful, but it should not be the only outcome measured during GLP-1 therapy.
A more complete evaluation may include:
- Waist circumference
- Body composition, when clinically appropriate
- Grip strength
- Ability to rise from a chair
- Walking speed
- Exercise performance
- Energy levels
- Dietary intake
- Laboratory indicators of nutritional status
- Bone mineral density in higher-risk individuals
- Ability to perform daily activities
- Long-term weight stability
A person can lose a substantial amount of weight while becoming weaker, less active, or nutritionally depleted. Conversely, someone whose weight loss has slowed may still be improving body composition, strength, glucose regulation, and cardiovascular fitness. The best outcome is not simply a smaller body. It is a stronger, healthier, and more functional body.
The Next Phase of GLP-1 Care
GLP-1-based medications are powerful tools, but medication alone cannot provide mechanical loading to bone, stimulate muscle adaptation, or supply the nutrients required to maintain healthy tissue.
The next phase of GLP-1 care must integrate:
- Progressive resistance and weight-bearing exercise
- Adequate, well-distributed protein
- Calcium-rich foods
- Sufficient vitamin D
- A varied, nutrient-dense diet
- Appropriate monitoring of strength and bone health
- A realistic plan for long-term weight maintenance
Protecting muscle and bone is not secondary to successful weight loss. It is part of successful weight loss. When treatment focuses on body composition, strength, function, and long-term health not simply the number on the scale GLP-1 therapy can become part of a more complete and sustainable approach to obesity care.
Disclaimer: This article is intended for scientific and educational purposes only. It does not provide individualized medical, nutritional, or exercise advice. GLP-1 medications should be used under the supervision of a qualified healthcare professional. Individuals with kidney disease, osteoporosis, previous fractures, mobility limitations, or other medical conditions should obtain personalized nutrition and exercise guidance.
References
Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., Lehmann, E. W., Lundgren, J. R., Juhl, C. R., Janus, C., Ternhamar, T., Stallknecht, B. M., Holst, J. J., Jørgensen, N. R., Jensen, J.-E. B., Madsbad, S., & Torekov, S. S. (2024). Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: A secondary analysis of a randomized clinical trial. JAMA Network Open, 7(6), e2416775. https://doi.org/10.1001/jamanetworkopen.2024.16775
Look, M., Dunn, J. P., Kushner, R. F., Cao, D., Harris, C., Gibble, T. H., Stefanski, A., & Griffin, R. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, obesity & metabolism, 27(5), 2720–2729. https://doi.org/10.1111/dom.16275
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., Jensen, J. B., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2021). Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. The New England journal of medicine, 384(18), 1719–1730. https://doi.org/10.1056/NEJMoa2028198
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., Gulati, M., Gupta, A., Horn, D., Kane, R. M., Saluja, J., Sannidhi, D., Stanford, F. C., & Callahan, E. A. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity, 33(8), 1475–1503. https://doi.org/10.1002/oby.24336
National Institutes of Health, Office of Dietary Supplements. (2026, June 22). Calcium: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/
National Institutes of Health, Office of Dietary Supplements. (2025, June 27). Vitamin D: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
Scott Butsch, W., Sulo, S., Chang, A. T., Kim, J. A., Kerr, K. W., Williams, D. R., Hegazi, R., Panchalingam, T., Goates, S., & Heymsfield, S. B. (2025). Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study. Obesity pillars, 15, 100186. https://doi.org/10.1016/j.obpill.2025.100186
Tan, Y., Liu, S., & Tang, Q. (2025). Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis. Acta diabetologica, 62(5), 589–606. https://doi.org/10.1007/s00592-025-02468-5
Wilding, J. P. H., Batterham, R. L., Calanna, S., Van Gaal, L. F., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society, 5(Suppl 1), A16–A17. https://doi.org/10.1210/jendso/bvab048.030
